Washington [US], February 18 (ANI): Around 50 per cent of patients who have been hospitalised with severe COVID-19 and who show raised levels of a protein called troponin cause damage to their hearts.
Study reveals cabozantinib most effective treatment for metastatic papillary kidney cancer ANI | Updated: Feb 14, 2021 11:12 IST
Washington [US], February 14 (ANI): In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice.
These findings were published in The Lancet.
There are currently no effective treatments for metastatic papillary kidney cancer, or metastatic pRCC, a rare subtype of kidney cancer. One study of 38 patients found that the average survival rate was eight months after diagnosis.
Washington [US], February 13 (ANI): A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumour.
Gene-based blood test for melanoma spread evaluates treatment progress: Study ANI | Updated: Feb 13, 2021 12:51 IST
Washington [US], February 13 (ANI): A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in people in the late stages of one of the most aggressive forms of skin cancer, a new study finds.
Led by NYU Grossman School of Medicine and Perlmutter Cancer Center researchers, the investigation looked at adults with undetectable levels of freely circulating tumor DNA (ctDNA) four weeks into drug treatment for metastatic melanoma tumors that cannot be removed surgically (unresectable).
Study sheds light on how women make choices about surgery to prevent ovarian cancer ANI | Updated: Feb 11, 2021 11:59 IST
London [UK], February 11 (ANI): A study by researchers at Queen Mary University in London has investigated how women who are at high risk of ovarian cancer make choices about possible preventive surgery.
Women who have BRCA1 and BRCA2 genetic mutations have a 17-44% lifetime risk of ovarian cancer. Scientists now believe that most ovarian cancers begin in the fallopian tubes, and so women at high risk can choose to undergo surgery to remove both their fallopian tubes and ovaries to reduce their risk. For those who have not yet reached menopause, there are difficult decisions around the order and timing of surgeries, as removing the ovaries will induce menopause.